Fig 1.
PRISMA flow diagram of the systematic search and screening.
Fig 2.
Geographical coverage of studies collecting individual participant data (IPD) on lymphatic filariasis (LF) infection or morbidity indicators measured pre- and post-intervention.
The 23 countries are shaded from red to yellow in accordance with the estimated abundance of IPD. The 39 countries shaded in blue are endemic for LF but had no studies identified. China is shaded green because of language barriers in assessing the abundance of IPD potentially available. The map was created using World (naturalearthdata.com) and the tmap package [38] for R (v. 4.2.2) [39].
Fig 3.
Frequency distribution (A) and estimated individual participant data (IPD) (B) of 138 eligible studies generating IPD on infection and morbidity indicators measured pre- and post-intervention, grouped by year of study publication.
Fig 4.
Frequency distribution of 138 eligible studies generating individual participant data (IPD) on lymphatic filariasis infection and morbidity indicators measured pre- and post-intervention, grouped by months of longest follow-up.
Table 1.
Estimated individual participant data (IPD) on lymphatic filariasis infection indicators measured pre- and post-intervention using different diagnostic indicators.
Table 2.
Estimated individual participant data (IPD) on lymphatic filariasis infection indicators measured pre- and post-intervention from different study designs.
Table 3.
Estimated individual participant data (IPD) on lymphatic filariasis infection and morbidity indictors measured pre- and post-intervention from studies reporting sex of trial participants.
Table 4.
Estimated individual participant data (IPD) on lymphatic filariasis infection and morbidity indicators measured pre- and post-intervention from studies reporting age eligibility of trial participants.
Table 5.
Estimated individual participant data (IPD) on lymphatic filariasis infection indicators measured pre- and post-intervention for the most frequently administered drug regimens.